wa private hospital, page-2

There is an absolutely massive potential for GSK to market Relenza and take market share from Tamiflu. We could be in for many years of production, but the market won't pay the multiple just yet... give it a few quarters with bullish comments from GSK and they just may. Tamiflu resistance will assist Relenza sales greatly and is the primary reason provided by GSK as to the shift in stockpiling attitude. Bodes well for LANI, more reason to diversify stockpiles.